StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Equities research analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective for the company.

Lipocine Stock Down 4.6 %

NASDAQ:LPCN opened at $5.02 on Monday. Lipocine has a 52 week low of $2.44 and a 52 week high of $11.79. The stock’s fifty day moving average is $5.17 and its two-hundred day moving average is $5.51. The stock has a market capitalization of $26.86 million, a price-to-earnings ratio of -6.61 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.